Skip to main content
NOVAVAX INC logo

NOVAVAX INC — Investor Relations & Filings

Ticker · NVAX ISIN · US6700024010 LEI · 529900J4GJHPEPQ23205 US Manufacturing
Open in API
Filings indexed 1,095 across all filing types
Latest filing 2010-03-17 Board/Management Inform…
Country US United States of America
Listing US NVAX

About NOVAVAX INC

https://www.novavax.com/?locale=US

Novavax Inc. is a biotechnology company that develops and commercializes vaccines to prevent serious infectious diseases. The company utilizes a proprietary, protein-based vaccine technology platform, which includes its novel Matrix-M™ adjuvant, to create its vaccine candidates. Its primary commercial product is a protein-based COVID-19 vaccine, Nuvaxovid™. Novavax's research and development pipeline is focused on addressing significant health needs, including influenza and a combination COVID-19-influenza vaccine. The company's strategy emphasizes advancing its pipeline assets and establishing strategic partnerships to maximize the global health impact of its technology.

Recent filings

Filing Released Lang Actions
8-K Filing
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The text specifically reports the departure of a senior officer, Raymond Hage, including details about his severance and confidentiality obligations. This matches the description of announcements related to changes in the company's board of directors or senior management. The document length is 2654 characters, which is relatively short and focused on management change rather than financial results or other report types. Therefore, the appropriate classification is Board/Management Information (MANG).
2010-03-17 English
4 Filing
Director's Dealing
2010-03-17 English
10-K Filing
Annual Report FY 2009
2010-03-16 English
S-3 Filing
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC by Novavax, Inc. It is a registration statement under the Securities Act of 1933 for the offering of securities including common stock, preferred stock, warrants, and units. The document includes a prospectus describing the securities to be offered, the terms of the offering, risk factors, and other related information. This type of filing is related to capital raising activities and updates on financing. It is not an annual report, earnings release, or management discussion, but rather a capital/financing update filing. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief notice, so it is not a Report Publication Announcement or Regulatory Filing fallback.
2010-03-16 English
8-K Filing
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions that the company issued a press release announcing financial results for the fourth quarter and year ended December 31, 2009, and that a conference call will be held. The document includes a press release as an exhibit but does not contain the full financial statements or detailed financial analysis itself. The length is 2764 characters, which is relatively short and consistent with a current report rather than a full earnings release or annual report. The document is primarily an announcement of financial results and a conference call, typical of an Earnings Release (ER) filing. Therefore, the best classification is Earnings Release (ER).
2010-03-12 English
8-K Filing
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The content includes announcements about the election of a new Executive Chairman and changes in board composition, specifically the non-compliance with Nasdaq listing rules due to changes in independent directors. These are changes related to the company's board of directors. There is no detailed financial data or full report content, but rather announcements about management and board changes. Therefore, this fits the category of Board/Management Information (MANG). The document length is over 6000 characters, indicating it is not a brief announcement but a full current report on these changes.
2010-02-18 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.